Your session is about to expire
← Back to Search
Educational Interventions for High Blood Pressure (MPC Trial)
N/A
Recruiting
Led By John Billimek, PhD
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up collected for analysis at baseline, upon completion of intervention period and upon completion of outcome assessment period at 1-month and 6-month follow up.
Awards & highlights
No Placebo-Only Group
Summary
This trial will compare two ways of teaching people with uncontrolled hypertension how to better manage their blood pressure medication.
Who is the study for?
This trial is for adults over 18 with uncontrolled high blood pressure (above 140/90 mmHg), who have visited the study clinic in the last year, and identify as Hispanic. They must speak Spanish or English. People with advanced chronic kidney disease (stage 4 or 5) cannot participate.
What is being tested?
The trial is testing two educational programs: 'Mi Propio Camino' and 'Habilidades para Controlar la Presion'. These are designed to help participants better adhere to their blood pressure medication regimen.
What are the potential side effects?
Since this trial focuses on educational interventions rather than medications, there are no direct side effects from drugs being tested. However, changes in how participants manage their medications could indirectly affect their health.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ collected for analysis at baseline, upon completion of intervention period and upon completion of outcome assessment period at 1-month and 6-month follow up.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~collected for analysis at baseline, upon completion of intervention period and upon completion of outcome assessment period at 1-month and 6-month follow up.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Medication Adherence (Objective)
Secondary study objectives
Activation of behavioral strategies
Blood Pressure
Medication Adherence (Subjective)
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Mi Propio Camino (MPC; My Own Way)Experimental Treatment1 Intervention
Participants will complete the MPC intervention alongside usual care for hypertension
Group II: Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)Active Control1 Intervention
Participants will complete the HCP intervention alongside usual care for hypertension.
Find a Location
Who is running the clinical trial?
University of California, IrvineLead Sponsor
566 Previous Clinical Trials
1,932,578 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,938 Previous Clinical Trials
47,791,798 Total Patients Enrolled
John Billimek, PhDPrincipal InvestigatorUniversity of California, Irvine
1 Previous Clinical Trials
190 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have severe chronic kidney disease stage 4 or 5.You are of Hispanic background.Your blood pressure is consistently higher than 140/90 mmHg and not managed with medication.
Research Study Groups:
This trial has the following groups:- Group 1: Mi Propio Camino (MPC; My Own Way)
- Group 2: Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.